SGLT (Sodium-Glucose Co-Transporter) Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Sodium-Glucose Co-Transporter (SGLT) is a member of the family of glucose transporters found in the human body. These play a significant function in reabsorbing glucose from the part in which they are present, depending upon the type of SGLT present. There are 2 types of SGLT present depending upon the location: SGLT-1 and SGLT-2. SGLT-1 is present in the brush border epithelium lined by the enterocytes, where it is responsible for glucose reabsorption from the intestine. SGLT-2 is present in the renal cortex, which absorbs glucose from the glomerular filtrate in the early and middle segments of the Proximal Convoluted Tubule (PCT).  These cotransporters play a significant role by regulating the glucose level in the body, hence, are a good target for drugs that aim to lower the blood glucose level in the body by indirect action, i.e., prevent absorption and increase excretion of glucose. Research is being conducted globally to discover new and novel molecules to be used as Anti-Diabetic agents. The development and launch of new products will thus increase the revenue of the market in the forecasted years. For instance, according to the International Diabetes Federation, in 2021, approximately 537 million people in the age bracket of 20-79 years globally are suffering from diabetes and counting. So, there is a huge market for the players to launch their products in the market in the near future.

A number of SGLT-1 inhibitors are on the market, while many are in ongoing clinical trials.  12 companies have various SGLT-1 inhibitors in their pipelines, with 8 products in various stages of clinical trials, 1 product in Phase 4, 1 product in Phase 3, 4 products in Phase 2, and 2 products in Phase 1 of the clinical trials. Moreover, 42 companies have various SGLT-2 Inhibitors in their pipelines, with 43 products in various stages of clinical trials, 17 products in Phase 4, 5 products in Phase 3, 4 products in Phase 2, and 12 products in Phase 1 of the clinical trials.

Key Developments

• In Jue 2023, FDA approved Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin HCl) as an adjuvant therapy to diet and exercise in children above 10 years of age and older with Type 2 diabetes.
• In May 2023, dual SGLT-1/2 Inhibitor- Inpefa (sotagliflozin) was approved by the FDA to reduce the risk of cardiovascular deaths and hospitalization for Heart failure in adults.
• In February 2023, Forxigo (dapagliflozin) was approved by the European Union (EU) to treat patients with Heart Failure with reduced ejection fraction.

Approved SGLT-1 Inhibitor drugs

• Inpefa (sotagliflozin)

 SGLT-1 Inhibitor drugs in Pipeline

• Licogliflozin (LIK066)
• Mizagliflozin (VGX-3235)
• Canalia (teneligliptin/canagliflozin)
• SY-009
• YG1699
• SY-008
• JTT-662
•  
• Approved SGLT-2 Inhibitor drugs
• Farxiga (dapagliflozin)
• Jardiance (empagliflozin)
• Invokana (canagliflozin)
• Inpefa (sotagliflozin)
• Suglat (ipragliflozin)
• Steglatro (ertugliflozin)
• Synjardy (empagliflozin/metformin)
• Enblo (enavogliflozin)
• Qtern (dapagliflozin/saxagliptin)
• Ruiqin (henagliflozin)
• Xigduo (dapagliflozin and metformin extended-release)
• Apleway (tofogliflozin)
• Vokanamet (canagliflozin/immediate release metformin FDC)
• Glyxambi (empagliflozin / linagliptin)
• DA-2811
• Lusefi (luseogliflozin
• Steglujan (ertugliflozin/sitagliptin

SGLT-2 Inhibitor drugs in Pipeline

• Brenzavvy (bexagliflozin)
• Qtern (dapagliflozin/saxagliptin)
• Remozen (remogliflozin etabonate)
• Ruiqin (henagliflozin)
• Xigduo (dapagliflozin and metformin extended-release)
• Apleway (tofogliflozin)
• licogliflozin (LIK066)
• Vokanamet (canagliflozin/immediate release metformin FDC)
• Glyxambi (empagliflozin / linagliptin)
• rongliflozin (HEC44616)
• DA-2811
• Lusefi (luseogliflozin)
• Steglujan (ertugliflozin/sitagliptin)
• Sujanu (ipragliflozin/sitagliptin)
• Trijardy XR (empagliflozin/linagliptin/metformin XR)
• YG1699
• CKD-378
• MAR701
• Qternmet XR (dapagliflozin/saxagliptin/metformin)
• Segluromet (ertugliflozin/metformin)
• dapagliflozin/sitagliptin
• dapagliflozin/sitagliptin (SID1903)
• henagliflozin/metformin (HR20033)
• janagliflozin
• pemafibrate/tofogliflozin (K-001)
• pioglitazone/metformin/dapagliflozin (BR3003)
• ISIS 388626
• dapagliflozin/linagliptin (IN-C009)
• dapagliflozin/metformin (HCP1801)
• dapagliflozin/metformin/sitagliptin (GMRx4)
• dapagliflozin/olmesartan medoxomil (ATB-101)
• dapagliflozin/semaglutide (NN9917)
• dapagliflozin/sitagliptin (DW6012)
• enavogliflozin/gemigliptin (DWJ1563)
• enavogliflozin/metformin (DWJ1525)

Clinical Activity and Developments of SGLT Inhibitors

As of June 2023, companies have approximately 8 products for 14 diseases. For these diseases, 7 trials are being conducted by players globally. For instance,

• In July 2022, Youngene Therapeutics completed a Phase 2 clinical trial to study the comparison of postprandial glucose after a mixed meal tolerance test, and the metabolic effects of Insulin withdrawal in a crossover study of the dual systemic SGLT1and SGLT2 Inhibitor YG1699, and the selective SGLT2 Inhibitor Dapagliflozin in subjects with Type 1 Diabetes

As of June 2023, 42 companies have approximately 43 products for 45 diseases. For these diseases, 393 trials are being conducted by players globally. For instance,

• In May 2023, Columbia University completed a Phase 4 clinical trial to study empagliflozin in Transthyretin Amyloid (ATTR) cardiomyopathy.
• In January 2023, Medanta, The Medicity completed a Phase 4 clinical trial to study the efficacy and safety of Dapagliflozin for the hospital management of patients with Type 2 Diabetes.
• In October 2022, the University of Campinas completed a Phase 4 trial to study the pharmacokinetics and dialyzability of Dapagliflozin in dialysis patients